Share Price, page-12307

The negative feelings around the FDA announcement and the fact they are still negotiating the end points is funny. It’s only feeling sand even the most rudimentary research would lead to a decent understanding of what the language in the announcement meant regarding the end point. The phase 2 was so successful that they need to ensure they are able to get meaningful results that support those end points without copying them.

This is a normal situation and not unexpected.

This is a buying opportunity.

Also there is a pricing issue where the market has priced in negative results for the Acadia quarterly. I don’t expect the result to be negative. I expect the next Acadia quarterly result will meet guidance and we will jump to about $15.